Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Medicyte and PRIMACYT Receive 300k Euro Grant to Develop Human Liver Cells for Cell-based Therapies

Published: Monday, March 05, 2012
Last Updated: Monday, March 05, 2012
Bookmark and Share
Cell-based therapies and the development of transplantable bioartificial livers to treat severe liver diseases still fail due to the limited availability of appropriate cells in large numbers and clinical quality. These failures are often related to the complex and difficult culturing of liver cells.

Medicyte’s upcyte® technology enables the expansion of human primary liver cells to large amounts and with consistent quality. Upcyte® hepatocytes are functionally equivalent to human primary liver cells and therefore suitable for use in cell-based bioartificial liver systems. PRIMACYT’s main expertise lies in the serum-free, long-term culturing of primary human hepatocytes and the development of cell culture media. Both companies now combine their knowledge to develop modified liver cells in large amounts for use in cell-based therapies.

Dr. Braspenning, Managing Director and CSO of Medicyte stated: “We are enthusiastic about working together with well-known German experts. I am sure that this collaboration will result in a vast pool of scientific data that support upcyte® as enabling technology of great value.”

Dr. Runge, Managing Director of PRIMACYT added: “The application and development of improved in-vitro systems for the treatment of severe liver disease is a key area of focus of our research and we believe the partnership with Medicyte and the University of Tübingen creates an ideal opportunity for our two companies to improve bioartificial liver devices.”

The three-year project is supported by a team from the University of Tübingen lead by Prof. Andreas Nüssler, a well-known liver cell expert. The Federal Ministry of Education and Research (BMBF) is supporting the joint effort out of the grant program “KMU-innovativ”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells
Medicyte to develop and market next generation, cell-based upcyte® cell products to the biopharma and academic research markets.
Thursday, March 28, 2013
Medicyte GmbH and Reinnervate Ltd to Collaborate
Companies announced a new product collaboration for the development of next generation predictive 3D cell toxicity assays.
Tuesday, July 10, 2012
Scientific News
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Editing of Embryos Approved in the UK
The Human Fertilisation and Embryology Authority (HFEA) has approved a research application from the Francis Crick Institute to use new "gene editing" techniques on human embryos.
Microbes Take Their Vitamins
Scientists exploit organisms' needs in order to track 'vitamin mimics' in bacteria.
Machine Learning Uncovers Unknown Bacterial Features
Technique robustly identified characteristic gene expression patterns in response to antibiotics, low oxygen conditions.
CRISPR-Cas9 Gene Editing Advances Again
UC Berkeley researchers have made a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60 percent when replacing a short stretch of DNA with another.
Disrupting Cell’s Supply Chain Freezes Cancer Virus
When the cancer-causing Epstein-Barr virus moves into a B-cell of the human immune system, it tricks the cell into rapidly making more copies of itself, each of which will carry the virus.
Why Do Some Infections Persist?
In preparing for the possibility of an antibiotic onslaught, some bacterial cultures adopt an all-for-one/one-for-all strategy that would make a socialist proud, University of Vermont researchers have found.
ASCB: A CELLebration of Cell Biology
The last major congress of the year, ASCB is less a platform for launching new products, but one for confirming and consolidating the trends that have emerged over the past 12 months.
Squeezing Cells into Stem Cells
EPFL scientists have developed a new method that helps cells turn in usable stem cells. The new approach involves “squeezing” cells with a gel, and paves the way for large-scale production of stem cells for medical purposes.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!